Send to:

Choose Destination
See comment in PubMed Commons below
Korean J Gastroenterol. 2013 Sep;62(3):169-73.

A rare case of free bowel perforation associated with infliximab treatment for stricturing Crohn's disease.

Author information

  • 1Departments of Internal Medicine, Pathology, and Surgery, Institute for Medical Science, Kosin University College of Medicine, Busan, Korea.


Crohn's disease is characterized by chronic transmural inflammation of the bowel and is associated with serious complications, such as bowel strictures, abscesses, fistula formation, and perforation. As neither medical nor surgical therapy provides a cure for Crohn's disease, the primary goals of therapy are to induce and maintain remission and prevent complications. As a biologic agent, infliximab, a monoclonal antibody to tumor necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease that does not respond to other medical therapies or surgery. Infliximab has proven to be very effective for inducing and maintaining remission in Crohn's disease; however, infliximab treatment has several potential complications. Here, we report a case of free perforation following a therapeutic response after an initial dose of infliximab for Crohn's disease. This is the first case report describing a free perforation in a Crohn's disease patient after an initial dose of infliximab.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for The Korean Society of Gastroenterology
    Loading ...
    Write to the Help Desk